Reimbursement List Extended But Pricing Reforms On The Horizon

BMI View: The key risk to pharmaceutical sales in Slovenia is the introduction of price erosion mechanisms and reforms regarding the interchangeability of drugs and advertising. While the addition of new innovative medicines to Slovenia's drug reimbursement list will be welcome news to the companies involved, the latest list includes new generic drugs and changes to maximum prices, which is expected to reduce state pharmaceutical expenditure.

To read the full article, please choose one of the following options: